2022, Number 1
<< Back Next >>
Rev Hematol Mex 2022; 23 (1)
Adherence to the ABVD scheme in patients with classical Hodgkin’s lymphoma and its prognostic impact
Colunga-Pedraza PR, Montelongo-Cepeda E, Lozano-Alcorta JA, Peña-Lozano SP, Colunga-Pedraza JE, Varela-Constantino A, Gutiérrez-Aguirre CH
Language: Spanish
References: 8
Page: 11-16
PDF size: 388.75 Kb.
ABSTRACT
Objective: To know the reasons for a delay in the administration of the ABVD scheme
and its impact on patients’ health in our center.
Materials and Methods: A descriptive, retrospective study without intervention
including patients with histologically confirmed diagnosis of Hodgkin’s lymphoma from
2015 to 2019 with first-line treatment ABVD in our center. Delay in the administration of
ABVD scheme was defined as the deferment of more than 48 hours in any administration.
Results: Forty-four patients were included; 28 females and 16 males with a median
age of 29.5 years (15-73). In total, 20 had a delay and 24 had good adherence to the
scheme. The main cause of delay was neutropenia in 9 patients. The complete response
rate, overall survival, and event-free survival were not significantly different in both
groups. In the subgroup of patients with low International Prognosis Score, event-free
survival was worse in patients with a delay in their treatment (75% at 4 years vs 33%).
Conclusions: We did not find any impact on overall survival or event-free survival
in patients with deferral of the ABVD scheme.
REFERENCES
Shanbhag S, Ambinder RF. Hodgkin lymphoma: A reviewand update on recent progress. CA Cancer J Clin 2018; 68:116-132. doi: 10.3322/caac.21438.
Boleti E, Mead GM. ABVD for Hodgkin’s lymphoma : fulldosechemotherapy without dose reductions or growthfactors. Ann Oncol 2007; 2: 376-380. doi: 10.1093/annonc/mdl397.
Cirillo M, Reinke S, Klapper W, Borchmann S. The translationalscience of Hodgkin lymphoma. Br J Haematol 2019;184: 30-4. doi: 10.1111/bjh.15658.
Dale D, McCarter G, Crawford J, Lyman G. Myelotoxicity anddose intensity of chemotherapy: Reporting practices fromrandomized clinical trials. J Natl Compr Canc Netw 2003;1: 440-454. doi: 10.6004/jnccn.2003.0038.
Hapgood G, Zheng Y, Sehn LH, Villa D, et al. Evaluation ofthe risk of relapse in classical Hodgkin lymphoma at eventfree-survival. Time points and survival comparison with thegeneral population in British Columbia. J Clin Oncol 2016;34: 2493-500. doi: 10.1200/JCO.2015.65.4194.
Chand VK, Link BK, Ritchie JM, Shannon M, WooldridgeJE. Neutropenia and febrile neutropenia in patients withHodgkin's lymphoma treated with doxorubicin (Adriamcyn),bleomycin, vinblastine and decarbazine (ABVD)chemotherapy. Leuk Lymphoma 2006; 47: 657-63. doi:10.1080/10428190500353430.
von Tresckow B, Plütschow A, Fuchs M, Klimm B, et al.Dose-Intensification in early unfavorable Hodgkin's lymphoma:Final analysis of the German Hodgkin Study GroupHD14 Trial. J Clin Oncol 2012; 30: 907-913. doi: 10.1200/JCO.2011.38.5807.
Jalali A, Ha FJ, Chong G, Grigg A, et al. Hodgkin lymphoma:an Australian experience of ABVD chemotherapy in themodern area. Ann Hematol 2016; 95: 809-16 doi: 10.1007/s00277-016-2611-4.
Full text